Protara Therapeutics (TARA) to Release Earnings on Wednesday

Protara Therapeutics (NASDAQ:TARA) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 9, 2026 at 9:30 AM ET.

Protara Therapeutics Stock Down 26.4%

Shares of TARA opened at $5.47 on Wednesday. Protara Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.82. The company’s fifty day moving average is $5.98 and its 200-day moving average is $5.15. The firm has a market cap of $282.42 million, a price-to-earnings ratio of -3.83 and a beta of 1.38.

Analyst Ratings Changes

A number of research analysts have recently commented on TARA shares. Piper Sandler initiated coverage on Protara Therapeutics in a report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Institutional Investors Weigh In On Protara Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in shares of Protara Therapeutics by 8.2% during the 3rd quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock worth $148,000 after acquiring an additional 2,596 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Protara Therapeutics by 26.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,736 shares of the company’s stock valued at $111,000 after acquiring an additional 4,383 shares during the period. Two Sigma Investments LP lifted its stake in Protara Therapeutics by 35.8% during the third quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock worth $85,000 after purchasing an additional 5,154 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Protara Therapeutics by 7.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 102,499 shares of the company’s stock valued at $546,000 after purchasing an additional 6,725 shares during the period. Finally, Quadrature Capital Ltd lifted its position in shares of Protara Therapeutics by 39.4% during the 4th quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock worth $129,000 after buying an additional 6,838 shares during the period. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.